Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome Following Lung Transplant
Guidance for a Medicare National Coverage Determination (NCD) which allows coverage of Extracorporeal Photopheresis (ECP) for the treatment of Bronchiolitis Obliterans Syndrome (BOS) following lung allograft transplantation under Coverage with Evidence Development (CED) with certain conditions.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: January 30, 2020
CMS issued a Medicare National Coverage Determination (NCD) on April 30, 2012 which allows coverage of Extracorporeal Photopheresis (ECP) for the treatment of Bronchiolitis Obliterans Syndrome (BOS) following lung allograft transplantation under Coverage with Evidence Development (CED) with certain conditions. The clinical study must address one or more aspects of the following question:
Prospectively, do Medicare beneficiaries who have received lung allografts, developed BOS refractory to standard immunosuppressive therapy, and received ECP, experience improved patient-centered health outcomes as indicated by:
- improved forced expiratory volume in one second (FEV1), or decreased rate of decline of FEV1;
- improved survival after transplant; and/or
- improved quality of life?
The results of additional clinical research may potentially provide sufficient evidence to inform future NCDs on the topic. CMS will maintain a list of all approved studies and post that list on this website.
INSTRUCTIONS FOR SUBMISSION OF APPLICATIONS
Approved studies
Study Title: Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Sponsor: Washington University School of Medicine
ClinicalTrials.gov Number: NCT02181257
CMS Approval Date: 01/07/2014
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.